Advances in diagnosis and treatment of angioimmunoblastic T-cell lymphoma.

Angioimmunoblastic T-cell lymphoma (AITL) is a peripheral T-cell lymphoma (PTCL) that originates from follicular helper T cells (Tfh) and represents a rare subtype of non-Hodgkin lymphoma (NHL). The disease is characterized by unique morphological, molecular, and clinical features, and exhibits aggressive behavior. Currently, there is no standard treatment protocol, and patients treated with first-line CHOP-like chemotherapy show low remission rates, high recurrence rates, and poor overall prognosis. In recent years, with the in-depth study of the molecular genetic mechanism of AITL, various novel therapies have shown potential in patients with relapsed/refractory (R/R) AITL. This review aims to summarize the latest developments in the molecular mechanisms and treatment strategies of AITL, with the goal of providing references for clinical practice.